DDCB coordinates infrastructure and expertise in the areas of drug discovery and chemical biology and makes it available to the scientific community. The DDCB platform provides services in assay development and chemical screening from medium to high throughput with a broad range of technologies including the DDCB-developed drug sensitivity and resistance testing platform. Our service portfolio also includes antibacterial screening, specialized assays for novel materials, repurposing of drugs, virtual screening, chemoinformatics, medicinal chemistry, as well as open access to a large national chemical collection, translational support and user base education.
Contact details
Nodes
Services
Recent user publications

Contact details

Platform Chair

Päivi Tammela
paivi.tammela@helsinki.fi

Nodes

Node/Host UniversityNode PI
HiLIFE – FIMM High Throughput Biomedicine Unit (HiLIFE-HTB), UH
Päivi Tammela
paivi.tammela@helsinki.fi
HiLIFE - Faculty of Pharmacy (HiLIFE-PHAR), UH
Henri Xhaard
henri.xhaard@helsinki.fi
Biocenter Kuopio – Molecular Modelling and Drug Design (BCK-PMC), UEF
Antti Poso
antti.poso@uef.fi
BioCity Turku – Turku Screening Unit/UTU (BCT-TSU), UTU
Michael Courtney
miccou@utu.fi
BioCity Turku – SBL-Computational Drug Design (BCT-SBL-CDD), ÅAU
Outi Salo-Ahen
outi.salo-ahen@abo.fi
Biocenter Kuopio – Medicinal Chemistry and Organic Synthesis Facilities (BCK-MCOS), UEF
Kristiina M. Huttunen
kristiina.huttunen@uef.fi

UEF: University of Eastern Finland; UH: University of Helsinki;  UTU: University of Turku, ÅAU: Åbo Akademi University

Services

  • Project and assay guidance and development support – all sites
  • Chemical screening and profiling – HiLIFE-HTB, HiLIFE-PHAR; BCT-TSU
  • Drug sensitivity and resistance screening (DSRT) and drug repurposing – HiLIFE-HTB
  • Imaging-based high-throughput screening – HiLIFE-HTB, BCT-TSU
  • Antimicrobial screening and follow-up assays – HiLIFE-PHAR
  • Chemoinformatics, molecular modeling, and virtual screening – BCK-PMC, HiLIFE-PHAR, and BCT-SBL-CDD
  • Synthesis of novel drug candidates and hit/lead optimisation – BCK-MCOS
  • Follow-up screening and testing – all sites
  • Access to a large national chemical collection – HiLIFE-HTB, BCT-TSU
Image

Recent user publications

Järvinen J, Adla SK, Tampio J, Jalkanen A, Sloan KB, Huttunen KM, Rautio J. A Novel Tertiary Carbamate Prodrug Strategy to Overcome Metabolic Barriers in Oral Ketamine Delivery. ChemMedChem, 2026, 21(2):e202500856. doi: 10.1002/cmdc.202500856

Momeny M, Tienhaara M, Sharma M, Chakroborty D, Varjus R, Takala I, Merisaari J, Padzik A, Vogt A, Paatero I, Elenius K, Laajala TD, Kurppa KJ, Westermarck J. DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer. EMBO Mol Med. 2024, 16, 1603-1629. doi: 10.1038/s44321-024-00088-0

Ali AE, Li LL, Courtney MJ, Pentikäinen OT, Postila PA. Atomistic simulations reveal impacts of missense mutations on the structure and function of SynGAP1. Brief Bioinform. 2024, 25, bbae458. doi: 10.1093/bib/bbae458

Saadabadi A, Wilkman L, Rantanen M, Koivisto A-P, Salo-Ahen OMH: Structure- and Ligand-Based Virtual Screening for Identification of Novel TRPV4 Antagonists. Molecules. 2025, 30, 100. doi: 10.3390/molecules30010100

Pietiäinen V, Polso M, Migh E, Guckelsberger C, Harmati M, Diosdi A, Turunen L, Hassinen A, Potdar S, Koponen A, Sebestyen EG, Kovacs F, Kriston A, Hollandi R, Burian K, Terhes G, Visnyovszki A, Fodor E, Lacza Z, Kantele A, Kolehmainen P, Kakkola L, Strandin T, Levanov L, Kallioniemi O, Kemeny L, Julkunen I, Vapalahti O, Buzas K, Paavolainen L, Horvath P, Hepojoki J. Image-based and machine learning-guided multiplexed serology test for SARS-CoV-2. Cell Rep Methods. 2023, 3, 100565. doi: 10.1016/j.crmeth.2023.100565.
Jokinen EM, Niemeläinen M, Kurkinen ST, Lehtonen JV, Lätti S, Postila PA, Pentikäinen OT, Niinivehmas S. Virtual Screening Strategy to Identify Retinoic Acid-Related Orphan Receptor γt Modulators. Molecules. 2023, 28, 3420. doi: 10.3390/molecules28083420
Asquith CRM, Temme L, East MP, Laitinen T, Pickett J, Kwarcinski FE, Sinha P, Wells CI, Johnson GL, Zutshi R, Drewry DH. Identification of 4-Anilinoquin(az)oline as a Cell-Active Protein Kinase Novel 3 (PKN3) Inhibitor Chemotype. ChemMedChem. 2022, e202200161. doi: 10.1002/cmdc.202200161

Malani D, Kumar A, Bruck O, Kontro M, Yadav B, Hellesoy M, Kuusanmaki H, Dufva O, Kankainen M, Eldfors S, Potdar S, Saarela J, Turunen L, Parsons A, Vastrik I, Kivinen K, Saarela J, Raty R, Lehto M, Wolf M, Gjertsen BT, Mustjoki S, Aittokallio T, Wennerberg K, Heckman CA, Kallioniemi O, Porkka K. Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discovery. 2022; 12, 1-14. doi: 10.1158/2159-8290.CD-21-0410.

Ilvesroiha E, Lauren P, Uema N, Kikuchi K, Takashima Y, Laaksonen T, Lajunen T. Establishing a simple perfusion cell culture system for light-activated liposomes. Sci Rep. 2023, 13, 2050. doi: 10.1038/s41598-023-29215-6.

Image
Image
Image